Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience

Calderón, Gerardo; Gonzalez-Izundegui, Daniel; Shan, K; Garcia-Valencia, Oscar A; Cifuentes, Lizeth; Campos, Alejandro; Collazo–Clavell, Maria L.; Shah, Meera; Hurley, Daniel L.; Lebdeh, Haitham S. Abu; Sharma, Mayank; Schmitz, Kristine; Clark, Matthew M.; Grothe, Karen; Mundi, Manpreet S.; Camilleri, Michael; Dayyeh, Barham K. Abu; Andrade, Maria Daniela Hurtado; Mokadem, Mohamad; Acosta, Andrés

doi:10.1038/s41366-021-01019-6

Cited by 26 publications

(24 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, the AOM response by medication during COVID-19 pandemic represented important differences to previously reported data [ 25 ]. Phentermine-topiramate showed the greatest %TBWL with 11.4% and 8.0% before and during the COVID-19 pandemic at 12 months, respectively.…”

Section: Discussioncontrasting

confidence: 99%

“…The proportion of patients achieving weight loss outcomes of >5%, >10%, >15%, and >20% before the pandemic was 77.7%, 44.7%. 17.7% and 11.8% and is similar to those observed in multicenter clinical studies [ 25 ]. In our cohort, categorical weight loss outcomes (5–20% TBWL) during the COVID-19 pandemic showed a lower proportion of patients achieving the same outcomes, with significant differences in those who achieved >10% and >15% TBWL.…”

Section: Discussionsupporting

confidence: 87%

“…The %TBWL achieved among patients prescribed an AOM before the COVID-19 pandemic showed similar results to other studies evaluating the efficacy of AOM ranging from 2.9% to 6.8% [ 25 , 26 , [30] , [31] , [32] , [33] , [34] ]. Our results showed a weight loss response very similar of about 5.3% at 3 months and 9.8% at 12-month follow-up.…”

Section: Discussionsupporting

confidence: 85%

“…Phentermine-topiramate showed the greatest %TBWL with 11.4% and 8.0% before and during the COVID-19 pandemic at 12 months, respectively. These overall robust response of phentermine-topiramate is clinically less in the COVID-19 group when compared to other studies, where the highest %TBWL at 12 months can reach about 12% at 1 year [ 25 ]. The weight loss response of naltrexone-bupropion before and during the COVID-19 pandemic at 12 months was 6.7 vs 3.7% TBWL, respectively, with significantly less %TBWL in all timepoints in the COVID-19 group, when compared to the preCOVID-19 group and published studies [ 33 ].…”

Section: Discussionmentioning

confidence: 69%

“…To date, most of the weight loss outcomes are derived from a focused testing of AOMs under strict control settings of randomized clinical trials (RCT). Few real-world studies often report different weight loss outcomes compared to previous RCTs [ 2 , 18 , 19 , 21 , [25] , [26] , [27] ]. Furthermore, the impact of limited healthcare access, confinement policies, and COVID-19 infection in individuals with overweight and obesity managed with AOM for weight control remains unknown [ 28 ].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

A comparison between weight loss outcomes with anti-obesity medications before and during Covid-19 pandemic at a tertiary weight management center

Rosa¹,

Ghusn²,

Sacoto³

et al. 2022

Obesity Pillars

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 99%

Section: Discussionsupporting

confidence: 87%

Section: Discussionsupporting

confidence: 85%

Section: Discussionmentioning

confidence: 69%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

A comparison between weight loss outcomes with anti-obesity medications before and during Covid-19 pandemic at a tertiary weight management center

Rosa¹,

Ghusn²,

Sacoto³

et al. 2022

Obesity Pillars

View full text Add to dashboard Cite

Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity

et al. 2022

Self Cite

View full text Add to dashboard Cite

ImportanceNo retrospective cohort study has assessed the effectiveness of semaglutide at doses used in randomized clinical trials to treat obesity (ie, 1.7 and 2.4 mg).ObjectiveTo study weight loss outcomes associated with semaglutide treatment at doses used in randomized clinical trials for patients with overweight or obesity.Design, Setting, and ParticipantsThis cohort study, conducted at a referral center for weight management, retrospectively collected data on the use of semaglutide for adults with overweight or obesity between January 1, 2021, and March 15, 2022, with a follow-up of up to 6 months. A total of 408 patients with a body mass index (BMI) of 27 or more were prescribed weekly semaglutide subcutaneous injections for 3 months or more. Patients with a history of bariatric procedures, taking other antiobesity medications, and with an active malignant neoplasm were excluded.ExposuresWeekly 1.7-mg or 2.4-mg semaglutide subcutaneous injections for 3 to 6 months.Main Outcomes and MeasuresThe primary end point was the percentage of weight loss. Secondary end points were the proportion of patients achieving weight loss of 5% or more, 10% or more, 15% or more, and 20% or more after 3 and 6 months and the percentage of weight loss for patients with or without type 2 diabetes after 3 and 6 months.ResultsThe study included 175 patients (132 women [75.4%]; mean [SD] age, 49.3 [12.5] years; mean [SD] BMI, 41.3 [9.1]) in the analysis at 3 months and 102 patients at 6 months. The mean (SD) weight loss after 3 months was 6.7 (4.4) kg, equivalent to a mean (SD) weight loss of 5.9% (3.7%) (P < .001), and the mean (SD) weight loss after 6 months was 12.3 (6.6) kg, equivalent to a mean (SD) weight loss of 10.9% (5.8%) (P < .001 from baseline). Of the 102 patients who were followed up at 6 months, 89 (87.3%) achieved weight loss of 5% or more, 56 (54.9%) achieved weight loss of 10% or more, 24 (23.5%) achieved weight loss of 15% or more, and 8 (7.8%) achieved weight loss of 20% or more. Patients with type 2 diabetes had a lower mean (SD) percentage weight loss at 3 and 6 months compared with those without type 2 diabetes: 3.9% (3.1%) vs 6.3% (3.7%) at 3 months (P = .001) and 7.2% (6.3%) vs 11.8% (5.3%) at 6 months (P = .005).Conclusions and RelevanceThe results of this cohort study suggest that weekly 1.7-mg and 2.4-mg doses of semaglutide were associated with weight loss similar to that seen in randomized clinical trials. Studies with longer periods of follow-up are needed to evaluate prolonged weight loss outcomes.

show abstract

Weight regain after total meal replacement very low‐calorie diet program with and with‐out anti‐obesity medications

Cifuentes,

Galbiati,

Mahmud

et al. 2023

Obesity Science & Practice

Self Cite

View full text Add to dashboard Cite

BackgroundVery low‐calorie diets (VLCDs) employing total meal replacement (TMR) offer substantial short‐term weight loss. Concurrently, anti‐obesity medications (AOMs) have shown promise as adjunctive treatments when combined with VLCDs.AimsThis study aimed to investigate the impact of adjuvant AOMs on weight loss and weight regain within a comprehensive lifestyle program.MethodsThis is a retrospective study of patients with obesity enrolled in VLCD/TMR programs, specifically the OPTIFAST program.ResultsData from 206 patients (68% women, mean age 52.39 ± 13.05 years, BMI 41.71 ± 7.04 kg/m2) were analyzed. Of these, 139 received no AOM (AOM‐), while 67 received AOMs (AOM+). Total body weight loss percentages (TWL%) at 6 and 18 months were −17.87% ± 7.02 and −12.10% ± 11.56, respectively. There was no significant difference in 6‐month weight loss between the AOM groups. However, the AOM + group exhibited lower weight regain (3.29 kg ± 10.19 vs. 7.61 kg ± 11.96; p = 0.006) and weight regain percentage (WR%) (31.5% ± 68.7 vs. 52.16% ± 64.4; p = 0.04) compared with the AOM‐ group.ConclusionThe findings highlighted the potential of AOMs and VLCD/TMR as effective strategies for long‐term weight management in individuals with obesity.

show abstract

Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience

Cited by 26 publications

References 34 publications

A comparison between weight loss outcomes with anti-obesity medications before and during Covid-19 pandemic at a tertiary weight management center

A comparison between weight loss outcomes with anti-obesity medications before and during Covid-19 pandemic at a tertiary weight management center

Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity

Weight regain after total meal replacement very low‐calorie diet program with and with‐out anti‐obesity medications

Contact Info

Product

Resources

About